Compare Harley-Davidson Inc (HOG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs TG Therapeutics Inc — how do they compare? Harley-Davidson Inc trades at $27.17 (market cap $2.78B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 2.7× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.75% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HOG | TGTX | |
|---|---|---|
Market Cap | $2.78B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $59.06 |
52-Week Low | $17.19 | $26.94 |
Enterprise Value | $3.19B | $7.84B |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $25.98, down 0.46% on the day, with a bullish technical signal from moving averages but mixed oscillators. Recent Q2 2026 earnings beat estimates at $0.75 per share versus $0.645 expected, though revenue declined year-over-year. The company raised full-year guidance, citing strong North American retail sales and cost-cutting initiatives under its 'Back to the Bricks' strategy, while returning Revolution Max engine production to the U.S.
The stock presents a value opportunity with a low P/E of 14.84 and P/S of 0.72, but faces headwinds from declining revenue and net margins. Analyst consensus is mixed with a $26 price target near the current price, indicating limited near-term upside. Key risks include competitive pressures, raw material cost inflation, and execution of the turnaround plan amid weakening profitability trends.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
